Medical, Legal, And Practice
Head & Neck
Lucida secures approval for AI-based prostate software
Lucida Medical has secured Lucida Medical has secured MDR Class IIb CE certification for its AI-based prostate cancer diagnosis software for MRI. New research on the AI tool was presented recently at the International Cancer Imaging Society meeting, and it will be available in Europe in early 2024.
October 22, 2023
Global variations persist in prostate MRI acquisition protocols
Global prostate MRI acquisition parameters continue to vary widely around the world -- and the variations are not good news for quality patient care, researchers from a top London facility have reported.
October 11, 2023
Spanish expert elaborates on value of prostate MRI guidelines
Familiarity with the updated guidelines for effective MRI acquisition, interpretation and reporting in diagnosis, whole-body staging, active surveillance, and local recurrence is essential for the modality's best use in the management of prostate cancer, a Spanish expert has asserted.
September 24, 2023
Which modality performs best for diagnosing prostate cancer relapse?
PET/CT and PET/MRI have gone head-to-head for detecting prostate cancer relapse in a new analysis that included 37 clinical studies and 8,709 patients -- with PET/MRI taking a slight lead.
September 3, 2023
Xeos Aura 10 PET/CT installed at Essen
University Medicine Essen's prostate cancer center in Germany recently implemented the Xeos Aura 10 specimen PET/CT imager.
August 17, 2023
MRI fusion-targeted plus systematic biopsy identifies prostate cancer
The combination of ultrasound and MRI fusion-targeted biopsies with systematic biopsies is more effective for identifying suspicious lesions than systematic biopsies alone in cases of prostate cancer, Scottish investigators have found.
July 26, 2023
Avenda spotlights AI prostate cancer study
AI software developer Avenda Health is highlighting clinical results that suggest its Unfold AI imaging software is effective in prostate cancer patients.
June 18, 2023
Delayed use of SPECT/CT can improve prostate cancer detection
Delaying SPECT/CT imaging by 15 hours after radiotracer injection can enable the identification of more tumors in patients with relapsed prostate cancer, a research group from the University Medical Center Hamburg-Eppendorf in Germany has asserted.
May 28, 2023
U.K. announces updates for consensus statements on bladder cancer
The U.K. Royal College of Radiologists (RCR) has announced it is updating its consensus statements on bladder cancer. The new document is due to be published later this year.
May 24, 2023
Curasight joins forces with Curium
Danish theranostics technology developer Curasight has formed a global partnership with nuclear medicine firm Curium to support the development of its uTrace radiopharmaceutical for use in prostate cancer.
May 2, 2023
Emerging PET tracer for prostate cancer displays promise
PET/CT imaging with F-18 PSMA-1007 detects significantly more prostate cancer than imaging using the standard F-18 fluorocholine radiotracer, according to clinical trial results published in the April issue of the
Journal of Nuclear Medicine
April 27, 2023
Prostate cancer study describes PET scoring system
A recent study from Japan has outlined a new PET scoring system for predicting whether prostate cancer patients will respond to treatment with investigational therapy Lu-PSMA-617.
April 23, 2023
Page 1 of 21